Abstract Renal cell carcinoma (RCC) displays strong resistance against many chemotherapeutic drugs. Overexpression of P-glycoprotein (Pgp) appears to be part of this resistance. The involvement of another resistance mechanism, involving the decreased activity of DNA topoisomerase II (topoII), remains uncertain. By culturing the human RCC lines RC2 and RC21 in the presence of increasing concentrations of etoposide, we derived the variant sublines RC2E, RC21A and RC21E, that had acquired approximately 30-, 60-and 90-fold resistance to this drug respectively. RC2E, RC21A and RC21E were approximately 50-, 5-and 400-fold crossresistant to doxorubicin respectively. RC2E and RC21E also showed cross-resistance (approximately 200-and 3500-fold respectively) to vinblastine. Quantitative differences in MDR1 and Pgp expression (elevated in RC2E and RC21E) and topoIIa (reduced in RC21E and RC21A) were demonstrated using Western blotting and the reverse transcriptase/polymerase chain reaction. Decreased amounts of topoIIa were re¯ected in a reduced activity of RC21A and RC21E as measured by unknotting phage P4 DNA. Qualitative changes of the topoIIa gene, such as point mutations in the motif B/ DNBS and DNA-binding regions, or dierences in methylation status of the promoter gene of RC21E, were not found. These cell lines represent a model of a solid tumor in which overexpression of Pgp, a combination of increased Pgp and decreased topoIIa, and a decrease of topoIIa are represented.
Introduction
Nearly 30% of patients with renal cell carcinoma (RCC) present with metastases at the time of diagnosis. As surgical treatment will be eective only for localized disease, curative therapy is not possible for these patients. Presently available chemotherapeutic drugs, administered according to standard scheduling, fail to achieve response rates of more than 7%, which might even partly represent an indirect cytotoxic eect (Yagoda et al. 1995) . The relative insensitivity of tumor cells to a broad range of cytotoxic agents is called multidrug resistance (MDR) . Insights into the mechanisms responsible for MDR should contribute to the development of more eective chemotherapeutic treatments for RCC. One of the best known resistance mechanisms implicated in MDR of RCC consists of overexpression of the MDR1 gene and its product P-glycoprotein (Pgp), an energy-dependent multidrug transmembrane transporter that prevents intracellular accumulation of cytotoxic drugs by rapidly extruding them (Kakehi et al. circumvented in vitro by chemosensitisers that interact with and block the drug-eux function of Pgp (Kakehi et al. 1988) . Clinical investigations using these reverting agents in combination with cytotoxic drugs have been initiated (Mickisch et al. 1990 ), but the results of these eorts have not been very rewarding so far (Mickisch et al. 1996; Motzer et al. 1995) , despite progress in the availability of modern chemosensitisers. These poor results may suggest that other mechanisms of MDR may be operational in RCC. Because RCC specimens display varying levels of Pgp expression (Kanamaru et al. 1989; Volm et al. 1993 ), Pgp-MDR may be only one of the contributing factors to the MDR of RCC. Other mechanisms of MDR have now been identi®ed. One of these, termed altered-topoisomerase MDR or at-MDR (Beck et al. 1994a; Hochhauser and Harris 1993) , is associated with decreased activity of the nuclear enzyme topoisomerase II (topoII). This enzyme can alter the topological state of DNA during cell-cycle activities (Wang 1987) . The action of topoII includes cleavage of double-stranded DNA, ATP-dependent passage of a secondary DNA strand through this cleavage site and rejoining of broken DNA (Oshero et al. 1994) . This happens at sites that are exposed to torsional stress of the highly compacted DNA incurred during DNA replication, RNA transcription, and segregation of chromosomes during mitosis. During the breaking and rejoining of double-stranded DNA, topoII and DNA form covalently bound complexes, termed cleavable complexes. The mechanism of action of certain topoII inhibitors, such as the epipodophylotoxins, is to stabilize these cleavable complexes (Liu et al. 1983) , thus preventing strand religation and further DNA processing, which eventually will lead to cell death (Beck et al. 1994b; Kamesaki et al. 1993; Pommier 1993) . The two mammalian isoforms of topoII, topoIIa (170 kDa) and topoIIb (180 kDa) (Drake et al. 1987; Tan et al. 1992) , have very similar regions, suggesting a comparable mode of action (Chung et al. 1989 ), but they dier in cell-cycle distribution. Expression of topoIIa varies during cell cycle, whereas topoIIb appears to be constant (Kimura et al. 1994; Woessner et al. 1990 ). Altered topoIIa activity, which can be caused by quantitative (Fry et al. 1991; Gudkov et al. 1993; Kim and Beck 1994; Ritke and Yalowich 1993) or qualitative (Danks et al. 1993; Hinds et al. 1991) changes, can result in reduced numbers of drug-stabilized cleavable complexes and is likely to in¯uence cellular sensitivity to topoII inhibitors.
We investigated whether at-MDR plays a role in the chemoresistance of RCC, as previously suggested (Volm et al. 1993) . Our aim was to develop a preclinical model for chemotherapeutic drug studies of RCC by establishing a panel of cloned cell lines expressing the at-MDR and/or Pgp-MDR phenotypes via pulsed treatment of previously unselected RCC cell lines with VP-16. The resistance of these newly established RCC sublines against topoII-inhibiting and non-topoisomerase-inhibiting drugs was assessed in relation to alterations in resistance-related gene expression, protein expression and protein activity. In addition, factors that may be responsible for the observed alterations were studied, such as gene mutations in certain regions of interest and methylation within the promoter region of the topoIIa gene.
Materials and methods

Cell culture and conditions
Two non-chemoselected human RCC cell lines, RC2 and RC21, originally established in our laboratory (Grossi et al. 1992 ) and three resistant sublines were examined. All RCC cell lines were cultured in DMEM-F12 medium supplemented with 7.5% fetal calf serum, 1 E/ml penicillin, 1lg/ml streptomycin and 2 mM glutamine (Gibco BRL Europe, Breda, The Netherlands) at 37°C in a humidi®ed atmosphere supplemented with 5% CO 2 . Resistant cell lines were derived from the parental cell lines by selection in increasing concentrations (0.033±10 lg/ml) of etoposide (BristolMeyers, Syracuse, USA). Nearly con¯uent cultures were exposed for 48 h to etoposide in concentrations that killed approximately 90% of the cells. After this treatment cultures were allowed to repopulate and then reexposed to a higher drug concentration for another 48 h. Thus, the etoposide dose was increased stepwise until cultures continued to grow exponentially in the presence of up to 10 lg/ml. The RC21A subline was obtained after 5 months, whereas the RC2E and RC21E lines were both isolated after approximately 8 months. Finally, the sublines were cloned by the limiting-dilution technique and characterized with respect to their resistance to etoposide and to vinblastine (E. Lilly Nederland, Nieuwegein, The Netherlands). The human leukemic CCRF-CEM cell line and its subline CEM/VM-1-5, resistant to teniposide (Danks et al. 1988) , served as controls for some of the assays. All cell cultures used for experiments were in logarithmic growth and had been found to be negative for Mycoplasma.
Growth inhibition assays
Chemosensitivities of parental cell lines and derived sublines were determined using the microtiter tetrazolium test (Romijn et al. 1988) . Exponentially growing cells were detached with trypsin/ EDTA (Gibco) and equal numbers of cells were plated with 100 ll medium in 96-well plates (Costar, Cambridge, Mass.). We used separate plates for each cell line and each drug. Plating densities were chosen such that exponential growth was maintained throughout the subsequent 4-day culture period. Drugs were added 24 h after plating in ten dierent concentrations, dissolved in 100 ll culture medium. Cytotoxic drugs used were etoposide, vinblastine, and doxorubicin (Pharmachemie, The Netherlands). After incubation with cytotoxic drugs for 72 h, 30 ll 5-mg/ml solution of dimethylthiazoldiphenyltetrazolium bromide (Sigma, St Louis, Mo.) in phosphate-buered saline was added. After 4 h the¯uid content of each well was aspirated carefully and the purple formazan precipitate dissolved upon shaking for 3 min in 100 ll 90% dimethylsulfoxide buered with 0.01 M glycine and 0.01 M NaCl (pH 10.5). Absorbances were measured at 570 nm using a BioRad microplate reader model 450 (BioRad, Hercules, Calif.). The reduction in absorbance at each drug concentration (8 wells) was expressed relative to the untreated controls. IC 50 values were determined from dose/inhibition curves. Resistance of sublines relative to parental lines was expressed as the ratio of their IC 50 values (the median inhibitory dose).
Topoisomerase unknotting activity
Isolated nuclei were used to obtain nuclear protein extracts as described before (Danks et al. 1988) . Exponentially growing cells (approximately 10 8 ) were permeabilized by incubation in hypotonic buer I (5 mM KH 2 PO 4 , 2 mM MgCl 2 , 4 mM dithiothreitol (DTT), 0.1 mM Na 2 EDTA, pH 7.0). When almost all cells were stained with trypan blue, they were pelleted at 400 g for 5 min and suspended in 2 ml buer II (buer I with 0.25 M sucrose). This suspension was layered over 3 ml buer III (buer I with 0.6 M sucrose) and centrifuged at 2000 g for 20 min. The pellet of isolated nuclei was then incubated in a half-volume of buer IV (5 mM KH 2 PO 4 , 4 mM DTT, 1 mM Na 2 EDTA, pH 7.0) on ice for 15 min. For 1.0 M salt extracts of nuclear protein, another halfvolume of buer V (40 mM TRIS, 2 M NaCl, 4 mM DTT, 20% glycerol, pH 7.5) was added. After incubation on ice for 30 min, the suspension was centrifuged at 100 000 g for 60 min, protein concentration was determined, and aliquots of this solution were stored at À80 C. In all buers proteinase inhibitors were included. P4 DNA (knotted phage DNA) was used as a substrate to measure the unknotting activity of topoII in the nuclear extracts, as described previously (Danks et al. 1988) . Activity pro®les were assessed by electrophoresis of the products in 0.7% agarose, subsequent staining of the gels with ethidium bromide and photographing under UV illumination.
Gene expression and mutation analysis
Total cellular RNA was extracted with the Stat-60 RNA isolation kit (Biotecx Laboratories Inc., Houston, Tex.), according to the manufacturer's directions, and used for single-strand conformational polymorphism (SSCP) analysis of point mutations (Danks et al. 1993 ) and quanti®tation by the reverse transcriptase/polymerase chain reaction (RT-PCR). RNA quantity and quality were checked spectrophotometrically. To generate cDNA from RNA templates, each sample tube included 0.5 lg total RNA; 5 mM MgCl 2 ; 1 mM each dGTP, dATP, dTTP, dCTP; 0.5 unit RNase inhibitor; 2.5 lM random primers; and 1.25 units reverse transcriptase, in a volume of 10 ll. All reagents used for PCR were from Promega (Madison, Wis.). The RT program used was 15 min at 42°C, 5 min at 99°C and 5 min at 5°C. To amplify speci®c regions from the cDNA, 40 ll was added of the following solution: 2 mM MgCl 2 , 0.5 lM each primer, 1.25 units Taq polymerase and, if used for SSCP analysis, 1 lCi [ 32 P]dATP. The program to amplify double-stranded DNA was 28 cycles of 30 s at 94°C, 30 s at 55°C, and 90 s at 72°C. Primer sets used for SSCP were for the ATPbinding sites motif B/DNBS (Danks et al. 1993 ) of topoIIa: 5¢-ATA ATA GAA TCA AGG GAA TTC CCA AAC TCG A-3¢ (sense) and 5¢-CTT GTA CTG CAG ACC CAC A-3¢ (antisense), and for the DNA-binding region adjacent to Tyr-805 of topoIIa: 5¢-CAA TTA GCT GGA TCC GTG GCT GAA ATG TC-3¢ (sense) and 5¢-CAG TAC CGA TTC CTG CAG CAC CAT TTA TC-3¢ (antisense). RT-PCR primer sets as described earlier were used for analysis of the expression of the gene for topoIIb (Tsai-P¯ugfelder et al. 1988) , MDR1 (Noonan et al. 1990) , and the glyceraldehyde-3-phosphate dehydrogenase gene (Gekeler et al. 1994) . Expression of the topoIIa gene was determined using the Tyr-B05 region primer set described above for SSCP analysis. PCR products were separated on 1.75% agarose gels at 150 V for 2 h, stained with ethidium bromide, visualized under UV illumination and photographed using Polaroid 667 ®lm. Products used for SSCP analysis (Danks et al. 1993 ) were heated to 99°C in formamide for 6 min, placed on ice allowing single DNA strands to retain their three-dimensional conformation, and electrophoresed in a gel composed of 6% acrylamide, 0.12% bisacrylamide, and 10% glycerol at 30 W for 9.5 h. Gels were put onto Whatman 3-mm paper, wrapped in plastic and exposed to X-ray ®lm (Kodak, Rochester, N.Y.).
Immunoblotting
For immunoblotting of topoIIa and topoIIb, whole-cell protein lysates were prepared as described previously (Danks et al. 1988) . After being scraped from culture¯asks, approximately 5´10 7 cells were lysed in 1 ml buer (10 mM TRIS/HCl, 1 mM MgCl 2 , 0.1 mM CaCl 2 , pH 7.8) containing proteolysis inhibitors (1 mM phenylmethylsulfonyl¯uoride, 1 mM benzamidine, 10 lg/ml soybean trypsin inhibitor, 50 lg/ml leupeptin, 1 lg/ml pepstatin, 20 lg/ml aprotinin) on ice for 20 min. Cells were checked for lysis by trypan blue and were then incubated for 20 min at 37°C after addition of 120 units DNase I (Sigma). The protein amount was quanti®ed (BioRad protein assay) and 1 ll sample buer (0.125 M TRIS/HCl, 20% glycerol, 4% SDS, 10% 2-mercaptoethanol, 0.004% bromophenol blue)/lg protein was added. Samples were boiled for 2 min, and were loaded (50±100 lg protein) onto a 5%± 15% gradient sodium dodecyl sulfate/polyacrylamide gel and electrophoresed for 3 h at 25 mA. Proteins were transferred to nitrocellulose (Schleicher & SchuÈ ll, Dassel, Germany) with a semidry blot apparatus (Milliblot, Millipore, USA) at 2.5 mA/cm 2 gel for 55 min. Membranes were incubated overnight at 4°C with either the anti-topoIIa polyclonal antibody MAC (Friche et al. 1992) , or anti-topoIIb polyclonal antibody (a kind gift of Dr. F. Boege, University of WuÈ rzburg, Germany), diluted in blotting milk (0.9% NaCl, 10 mM TRIS/HCl pH 7.5, 0.02% sodium azide, 5% dry milk, 3% IgG-free bovine serum albumin, 0.2% Tween-20). Membranes were then incubated with alkaline-phosphatase-linked goat anti-(rabbit Ig) secondary antibody, and stained with 0.003% 5-bromo-4-chloro-3-indolyl phosphate and 0.006% nitrobluetetrazolium chloride in TRIS buer (100 mM NaCl, 5 mM MgCl 2 , 100 mM TRIS, pH 9.5) until speci®c bands appeared. For detection of Pgp, cells were solubilized in 20 mM TRIS/HCl (pH 7.4), containing 1 mM MgCl 2 , 2% v/v Triton X-100, 0.1% w/v SDS, 1% v/v dimethylsulfoxide and proteolysis inhibitors, overnight at 4°C. After centrifugation, the resulting supernatants were ®ltered (0.45 lm ®lter) and immediately loaded onto a 7% acrylamide gel. Resolved proteins were transferred to nitrocellulose, which was incubated with the anti-Pgp monoclonal antibody C219. Further incubations were successively performed with biotinylated goat anti-(mouse IgG2a), streptavidin-biotinylated horseradish peroxidase complex, and freshly prepared chemiluminescence Western blotting detection reagent (Boehringer, Mannheim, Germany). Finally, X-ray ®lms were exposed to membranes for 0.2±1 min.
Methylation status of promoter DNA Genomic DNA was isolated from approximately 2´10 7 cells, and digested as previously described (Lo¯in et al. 1994) . Restriction enzymes StyI and XmnI (New England Biolabs, Beverly, Mass.) were used to obtain the promoter region of the topoIIa gene (Hochhauser et al. 1992 ). This 623-bp fragment was digested with the restriction enzymes HhaI, HpaII and MspI (New England Biolabs). All products were separated on 1.4% agarose gel, transferred to nylon membranes, and hybridized with a 32 P-labelled topoIIa-promoter probe (a generous gift of Dr. I.D. Hickson, Oxford, England). X-ray ®lms were exposed to membranes for AE7 days.
Results
Expression of resistance and cross-resistance in etoposide-selected RCC lines Cells were exposed to chemoresistance-inducing regimens until continuous growth was observed in the presence of 10 lg etoposide/ml. Three sublines thus obtained, RC2E derived from RC2, and RC21A and RC21E, both derived from RC21, were used for further studies. Expression of MDR phenotypes in these sublines was tested by sensitivity assays with etoposide and doxorubicin, both inhibitors of topoII, or vinblastine, which does not inhibit topoII. Dose/response curves for the parental and derived cell lines are shown in Fig. 1 . The results demonstrate that all the selected sublines have a reduced sensitivity to the topoII-inhibiting drugs, as compared to the parental cell lines. The results of several experiments are summarized in Table 1 . Resistance to etoposide was increased approximately 30-fold for RC2E, 60-fold/RC21A and 90-fold for RC21E. Enhanced resistance to doxorubicin (approximately 50-, 5-, 400-fold, respectively) was also observed for the same set of cell lines. However, since etoposide and doxorubicin are also known to be potential substrates for Pgp, and RCC can express Pgp, the possible involvement of Pgp was examined as well, by evaluation of the crossresistance to vinblastine. RC2E and RC21E were indeed strongly cross-resistant to vinblastine (approximately 200-and 3500-fold increase respectively), whereas RC21A appeared to be as sensitive as the parental RC21 cell line (Fig. 1, Table 1 ).
The stability of this resistance was checked monthly for more than 1 year. MDR patterns of RC21E and RC21A were stable during this period even without monthly maintenance drug dosages of 1 lg/ml etoposide for 2 days. RC2E lost its resistance 8 months after the last concentration level of etoposide used (10 lg/ml).
Topoisomerase unknotting activity
The ATP-dependent strand-passing activity of topoII in nuclear extracts of the cell lines was measured using P4 DNA as a substrate. P4 DNA was less eectively un- Figure 2 shows separate P4-DNA-unknotting assays of the resistant lines compared to the parental cell line. The amount of nuclear protein required for complete P4 DNA unknotting by the resistant cell lines RC21E and RC21A was double that for RC21. The decreased ability of comparable amounts of nuclear protein to unknot P4 DNA indicates that resistance to etoposide of RC21E and RC21A may be a consequence of altered topoisomerase-associated MDR. Because we saw decreased topoII unknotting activity in the resistant sublines RC21A and RC21E, but not in the resistant line RC2E, we checked the expression of MDR1-related genes.
RT-PCR studies
Expression of the resistance-associated genes was examined by RT-PCR, using speci®c primers. Results are shown in Fig. 3 . The level of expression of the``housekeeping'' gene for glyceraldehyde-3-phosphate dehydrogenase was used as a control for cDNA quantity. The parental RC2 line and its resistant subline RC2E had the same topoIIa mRNA expression (Fig. 3 upper  panel) . In contrast, sublines RC21E and RC21A showed a decreased level of topoIIa mRNA, compared to their parental line. RC2E, which expressed resistance to vinblastine, showed a slightly increased MDR1 mRNA expression compared to RC2 (Fig. 3 lower panel) . In contrast to the vinblastine-sensitive lines RC21 and RC21A, the resistant subline RC21E showed MDR1 expression. Expression signals of the topoIIb gene were faint, but expression in RC2E and RC21A ( Fig. 3 upper panel) appeared to be slightly increased compared to their parental lines.
Immunoblotting
The contents of Pgp, topoIIa and topoIIb were analyzed by Western blotting of whole-cell protein extracted from the parental cell lines and the derived sublines (Fig. 4) . Protein expressions were analyzed for at least three 
SSCP analysis
To try to account for the decreased expression of topoIIa protein, we examined by SSCP analysis two regions of the topoIIa gene where, relatively infrequently, point mutations leading to functional aberrations are known to occur (Danks et al. 1993) , changing the ATP-binding region (ATP-binding sites: motif B and DNBS) and the DNA-binding region (adjacent to . Mutations in the ATP-and DNA-binding regions, as seen in the CEM/VM-1-5 cells, may result in changed protein con®guration and decreased enzymatic activity.
Results of the analysis of nucleotides 1323±1534, containing the motif B and DNBS sites, are shown in Fig. 5 . No conformational dierences were found in the singlestranded PCR products of all of the RCC lines, as they migrated as those of the CEM cell line, which has no mutations. Only the PCR product of CEM/VM-1-5 cDNA showed a third band, which is due to a mutation in this region in one of its alleles. Also, no alterations were found in the ATP-binding region of the parental and resistant RCC cell lines (results not shown).
Methylation status
Since methylation of gene promoter sites can result in gene inactivation (Cedar 1988) , we examined the methylation status of the promoter region of the topoIIa gene in RC21E and RC21 cells. RC21A was not analyzed because this is a precursor of RC21E, unlikely to exhibit changes that are not seen in the latter line. Restriction enzyme analysis using HhaI and HpaII (cutting at unmethylated sites only) and MspI (cutting at the same sites as HpaII regardless of the methylation status) was applied to identify possible resistance-related dierences (Harker et al. 1995; Jones and Buckley 1990) . Figure 6 shows that identical patterns were obtained for RC21 and RC21E topoIIa-gene-promoter DNA with HhaI (94-bp and 529-bp fragments), HpaII (43-bp, 241-bp and 338-bp fragments) or with MspI (the same fragments as with HpaII). We conclude that hypermethylation of the promoter region of the topoIIa gene does not seem to play an important role in the decreased transcription level of topoIIa RNA. Fig. 4 Immunoblot analysis of topoIIa, topoIIb and P-glycoprotein (Pgp) from RC21, RC21A, RC21E, RC2 and RC2E cells. The expressions in the cell lines demonstrated were obtained in one gel run for each protein indicated. For analysis, cell fractions from each cell line were subjected to SDS-PAGE and the separated proteins were transferred to a nitrocellulose ®lter; the ®lters were then prepared as indicated in Materials and methods 
Discussion
The nuclear enzymes topoI and topoII are the targets of many known drugs that stabilize complexes of broken DNA strands and protein (Pommier 1993) . Most of these drugs stabilize covalent complexes of topoII and broken DNA strands that are formed during speci®c phases of the cell cycle, leading to apoptotic cell death by mechanisms that are incompletely understood. Alterations of the level of topoII activity, which can be caused by a variety of mechanisms such as topoIIa gene mutations (Danks et al. 1993; Hinds et al. 1991; Nitiss et al. 1993 ), post-translational modi®cations (Devore et al. 1992; Takano et al. 1991) , or a reduced amount of the enzyme Gudkov et al. 1993; Liu 1989) , will therefore modulate the eectiveness of topoII-speci®c drugs. If fewer complexes are stabilized, cells will be less vulnerable to cytotoxic drugs and may become resistant. To date, the majority of chemoresistance studies in RCC have focused on the expression of Pgp, the MDR1 gene product, as a cause of resistance to a broad range of antineoplastic drugs. Since there is a considerable variability of Pgp expression in RCC, the unrewarding results of chemotherapeutic treatment for RCC can not exclusively be explained by Pgp-mediated resistance. In the present study, we found that at-MDR resistance, associated with a reduced expression of the topoIIa gene and protein, may contribute to the MDR phenotype in RCC.
Cloned drug-resistant sublines RC2E, RC21A and RC21E were generated from the parental, non-chemoselected, human RCC cell lines RC2 and RC21 by stepwise exposure of cell cultures to increasing concentrations of etoposide. We showed that RC2E overexpressed Pgp, that RC21A exhibited a decreased amount of topoIIa, and that RC21E developed both forms of resistance. As a consequence, improvement of the chemotherapeutic treatment of RCC may require drugs that are substrates for neither Pgp-mediated MDR nor nonPgp-mediated MDR, such as at-MDR. Our panel of cell lines, therefore, oers a new tissue-culture model that can be used to identify novel chemotherapeutic agents, including topoIIa-interactive drugs, and to investigate the mechanisms of at-MDR resistance in RCC. It may be possible that other mechanisms, which not have been investigated yet, such as glutathione content or the activity of glutathione transferase, may be part of the MDR phenotype as well. Involvement of multidrugresistance-associated protein 1 (MRP1), a cell-membrane-bound protein, is excluded in these cell lines.
We observed a reduced growth rate and altered growth pattern or cell cultures of RCC cells expressing reduced amounts of topoIIa protein. In contrast to the parental RC21 cell line, the sublines continue to proliferate after reaching con¯uence, resulting in the formation of multilayer colonies. Reduced growth rate has also been described for other cancer cell lines (Danks et al. 1988) , which may complicate the interpretation of the growth-inhibiting eects of drugs. However, the reduced cytotoxic eects of topoII-inhibiting drugs will likely lead to quanti®able tumor expansion. Another consequence of the reduced growth rate can be that the cloning procedure of the resistant sublines may not have resulted in the selection of the most resistant cells. The cloning technique, which selects colonies formed from a single cell, will favor faster-growing cells. Thus, for reliable comparisons, growth-adjusted IC 50 values should be used for the determination of cytotoxicity.
Occasionally, an indirectly correlated expression of the topoI and topoIIa genes is seen in cells resistant to topoisomerase inhibitors, which might be interpreted as a compensatory mechanism (Woessner et al. 1992 ). Others found a direct correlation between topoIIa and topoIIb gene expression (Brown et al. 1995; Kaufmann et al. 1994) . We observed increased topoIIb protein expression in RC21A cells and reduced topoIIa, which would be in accordance with the idea of compensation. It remains unclear why RC2E expresses an increased amount of topoIIb protein, without reduced expression of topoIIa. Thus, up-regulation of topoIIb protein might be regarded as an optional mechanism of compensation for a decrease in topoIIa protein. However, topoIIb gene expression does not seem to aect cellular P4-DNA-unknotting activity, since RC2E, with increased topoIIb expression, showed unaected unknotting activity, compared to the parental RC2. In addition, RC21A showed decreased unknotting activity, although it expresses increased topoIIb protein, compared to parental RC21.
Decreased amounts of topoIIa, seen in RC21A and RC21E, are matched by decreased mRNA expression, suggesting that these lines express the at-MDR phenotype. Also, we detected no point mutations in the regions of the gene encoding the motif B/DNBS and Tyr-805, as analyzed with SSCP. These regions represent areas in the topoIIa gene sequences in which some point mutations were found in other malignancies (Danks et al. 1993) . The occurrence of mutations in other parts of the gene cannot be excluded, however. On the other hand, test conditions used to run the gels are claimed to be highly ecient for the speci®ed regions. Nevertheless, it appears that reduced activity of topoII in the drug-resistant sublines, as assessed by P4-DNA-unknotting activity, is due to decreased expression of the topoIIa gene.
In our initial investigations for a possible cause of the decreased topoIIa gene expression, we measured transcription activity of the topoIIa gene, in part by comparing the methylation status of the promoter region of the topoIIa gene in the RC21 and RC21E cell lines; we found no dierences between these cell lines (Fig. 6) , and the topoIIa gene promoter was hypomethylated. Methylation of RC21A was not investigated since RC21E was established by continuous exposure of RC21A to etoposide, when decrease of topoIIa gene expression had already taken place. It is, therefore, highly unlikely that changes in RC21A could be detected that would not found in RC21E also. Our results suggest that a decrease in topoIIa protein in RC21E cells is likely due to other mechanisms of gene regulation. One possible mechanism for such gene regulation is transactivation of the Sp1 and Sp3 proteins. These proteins might activate or inhibit the promoter region of the topoIIa gene respectively, as has been described in other cell lines (Kubo et al. 1995) .
RCC cells, which are almost always resistant to a broad range of antineoplastic drugs, are well known to express MDR1 and Pgp. The established RCC cell lines overexpress MDR1 and are highly resistant to vinblastine, but it has become clear that at-MDR likely contributes to the drug-resistance pro®le in RCC. The observed resistance to topoII inhibitors of at-MDR RCC cell lines appears to be related to a decrease in topoIIa gene and protein expression. Expression of the topoIIa gene in clinical specimens, when primary cultures are used, has already indicated a possible involvement of at-MDR in RCC (Volm et al. 1993 ). However, a direct relationship between expression and resistance was not investigated in that study. The immortal and cloned cell lines described in this paper showed such a relationship in RCC cells. These lines, with their de®ned resistance pro®les and expression patterns of resistance markers, oer a model suitable for extensive in vitro investigation of drug development in RCC, and for elucidating the mechanism of topoII activity and regulation of gene expression. Future studies with this model should yield information on the drug-resistance pro®les of new chemotherapeutic agents and may contribute to improved treatment of clinical RCC.
